TCTMD

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

WASHINGTON, DC—Two-year results from the ABSORB III study presented today at the American College of Cardiology 2017 Scientific Session show that the Absorb GT1 bioresorbable vascular scaffold (BVS, ...
Medscape

Negative Data Piling Up on Absorb Bioresorbable Scaffold

AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...
Medscape

ABSORB-3 at 2 Years: More CV Events With Absorb BVS vs Xience

WASHINGTON, DC — Patients who received the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) in the ABSORB-3 trial showed a primary outcome, counting only events occurring between the ...
Healio

ABSORB III 2-year results suggest optimal techniques may be key

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — At 2 years, the cumulative rate of target ...